The annual EP Vantage 2017 Preview discusses what’s in store for biopharma in the coming year.
Despite the uncertainty that loomed over the pharma and biotech sectors with unexpected outcomes from both the US presidential election and UK’s vote to leave the EU, 2017 may bring renewed energy to the industry with potential for more corporate activity and cash flow.
According to the report, 2017 will see:
EP Vantage is Evaluate’s independent editorial team providing daily news, commentary and analysis driven by Evaluate data and forecasts.